UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
(Exact name of Registrant as Specified in Its Charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s Telephone Number, Including Area Code:
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 3.01. | Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
On January 16, 2024, Spyre Therapeutics, Inc. (the “Company”) received approval from the Listing Qualifications Staff of The Nasdaq Stock Market LLC to transfer the listing of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), from The Nasdaq Capital Market to The Nasdaq Global Select Market, effective as of the opening of business on January 19, 2024. The Common Stock will continue to trade under the symbol “SYRE.” The Nasdaq Global Select Market operates in substantially the same manner as The Nasdaq Capital Market and listed companies must meet certain financial requirements and comply with Nasdaq’s corporate governance requirements.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: January 18, 2024 | SPYRE THERAPEUTICS, INC. | |||||
| By: | /s/ Cameron Turtle | |||||
| Cameron Turtle | ||||||
| Chief Executive Officer | ||||||
Document and Entity Information |
Jan. 16, 2024 |
|---|---|
| Cover [Abstract] | |
| Security Exchange Name | NASDAQ |
| Amendment Flag | false |
| Entity Central Index Key | 0001636282 |
| Document Type | 8-K |
| Document Period End Date | Jan. 16, 2024 |
| Entity Registrant Name | SPYRE THERAPEUTICS, INC. |
| Entity Incorporation State Country Code | DE |
| Entity File Number | 001-37722 |
| Entity Tax Identification Number | 46-4312787 |
| Entity Address, Address Line One | 221 Crescent Street |
| Entity Address, Address Line Two | Building 23 |
| Entity Address, Address Line Three | Suite 105 |
| Entity Address, City or Town | Waltham |
| Entity Address, State or Province | MA |
| Entity Address, Postal Zip Code | 02453 |
| City Area Code | 617 |
| Local Phone Number | 651-5940 |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Security 12b Title | Common stock, $0.0001 Par Value |
| Trading Symbol | SYRE |
| Entity Emerging Growth Company | false |
-8?20$3;8T.P6BP^0"X99K>]9!:G